SurModics Inc - Company Profile
Powered by 
All the sales intelligence you need on SurModics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how SurModics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with SurModics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
SurModics Inc (SurModics) is a provider of in vitro diagnostic (IVD) and medical device technologies to healthcare sector. The company develops and commercializes vascular intervention medical devices and performance coatings. SurModics' major products include drug-coated balloons, mechanical thrombectomy devices, radial access balloon catheters, and performance coating reagents and IVD components like protein stabilizers and antigens. The company's products serve customers in the medical device and diagnostic industries, with applications in neurovascular, peripheral, coronary, and structural heart markets. Surmodics distributes its products through original equipment manufacturer suppliers, distributors, and directly to healthcare providers. SurModics is headquartered in Eden Prairie, Minnesota, the US.
Headquarters
United States of America
Address
9924 W 74th St, Eden Prairie, Minnesota, 55344
Website
www.surmodics.com
Telephone
1 952 5007000
No of Employees
389
Industry
Medical Equipment
Revenue (2024)
$126.1M
SurModics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| In Vitro Diagnostics Technologies: | PhotoLink |
| Antigens | BioFX |
| Antibodies | Pounce |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In April, the company announced the launch of Pounce XL Thrombectomy System for rapid endovascular removal of acute or chronic clot from peripheral arteries. |
| 2024 | Regulatory Approval | In December, the company received additional FDA 510(k) clearance for 018 Hydrophilic Coated OTW PTA balloon dilatation catheter. |
| 2024 | Others | In January, the company announces successful early clinical Use of the Pounce LP (Low Profile) thrombectomy system, that is designed to address a critical, unmet need by facilitating the removal of thrombi and emboli below the knee. |
Competitor Comparison
| Key Parameters | SurModics Inc | Nihon Kohden Corp | Hydromer Inc | B. Braun Melsungen AG | Immucor Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Japan | United States of America | Germany | United States of America |
| City | Eden Prairie | Shinjuku-Ku | Concord | Melsungen | Norcross |
| State/Province | Minnesota | Tokyo | North Carolina | Hessen | Georgia |
| No. of Employees | 389 | 6,114 | 36 | - | - |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gary R. Maharaj | Chief Executive Officer; Director; President | Executive Board | 2010 | 61 |
| Susan E. Knight | Chair | Executive Board | 2015 | 71 |
| Timothy J. Arens | Chief Financial Officer; Senior Vice President - Finance and Information Technology | Senior Management | 2020 | 57 |
| Teryl L.W. Sides | President - Vascular Interventions; Senior Vice President - Product Development | Senior Management | 2022 | 55 |
| Gordon S. Weber | Secretary; General Counsel; Senior Vice President - Legal | Senior Management | 2020 | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer